跳至主要内容
临床试验/NL-OMON50794
NL-OMON50794尚未招募不适用

AntiBody response in Risk groups to COrona Vaccination treated in the Adrz hospital: - AbriCoVa

Interne Geneeskunde0 个研究点目标入组 120 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Study participant belongs to either of the 6 defined groups and is planned for
  • vaccination with the BNT162b2 or the mRNA1273 vaccine according to the National
  • Institute for Public Health guideline, i.e.:
  • Inflammatory bowel disease and on treatment for at least 6 weeks with
  • anti-TNF agents (infliximab, adalimumab and biosimilars)
  • post kidney transplantation and on immunosuppressants
  • Treated with B-cell depleting, antiCD20 (Obinituzumab or Rituximab)
  • monotherapy for a hematological malignancy in the past 6 months
  • Chronic lymphocytic leukemia (CLL), irrespective of stage, not treated for
  • CLL in the past 6 months prior to the first vaccination and no treatment
  • expected within 4 weeks of the second vaccination
  • Advanced solid malignancy and on treatment for at least 6 weeks with one or
  • more of the following agents: doxorubicin, cyclophosphamide, docetaxel,
  • cisplatinum, etoposide, irinotecan
  • healthy volunteers
  • Study participant is older than 17 years and willing to undergo vaccination
  • Study participant is able to give written informed consent
  • Study participant is able to visit the ADRZ for the scheduled laboratory

排除标准

  • History of a documented SARS COV-2 infection
  • Considered as high risk for a hypersensitivity reaction

研究者

发起方
Interne Geneeskunde

相似试验